ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "osteoporosis"

  • Abstract Number: 1025 • 2016 ACR/ARHP Annual Meeting

    Assessment of the Effects of Switching Bisphosphonates to Denosumab or Daily Teriparatide in Patients with Rheumatoid Arthritis

    Kosuke Ebina1, Makoto Hirao2, Jun Hashimoto3, Masao Yukioka4, Takaaki Noguchi5 and Hideki Yoshikawa6, 1Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan, 2Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Suita, Japan, 3Dept of Rheumatology, Osaka-Minami Medical Center, Kawachinagano City, Japan, 4Orthopedic Surgery, Yukioka Hospital, Osaka, Japan, 5Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Osaka, Japan, 6Department of Orthopedics, Osaka University Graduate School of Medicine, Suita Osaka, Japan

    Background/Purpose: The efficacies of switching bisphosphonate (BP) to denosumab (DMAb), an anti-RANKL antibody which strongly inhibits bone resorption, or daily teriparatide (TPTD), a bone anabolic…
  • Abstract Number: 1026 • 2016 ACR/ARHP Annual Meeting

    Morphea-like Skin Lesions Reported in the Phase 3 Long-Term Odanacatib Fracture Trial and Extension in Postmenopausal Women with Osteoporosis

    Kenneth G. Saag1, Tobie de Villiers2, Peter Alexandersen3, Heidi Jacobe4, Carrie Kovarik5, Victoria P. Werth6, Albert Leung7, Avani Desai-Merchant8, Julie Mattaliano8 and Deborah Gurner8, 1Department of Medicine, Division of Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, USA, Birmingham, AL, 2Mediclinic Panorama and Department of Obstetrics & Gynecology, University of Stellenbosch, Cape Town, South Africa, Cape Town, South Africa, 3Center for Clinical and Basic Research, Vejle, Denmark, Ballerup, Denmark, 4Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, 5Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, 6Philadelphia VAMC, Philadelphia, PA, USA, Philadelphia, PA, 7Formerly Merck & Co., Inc., Kenilworth, NJ, USA, Kenilworth, NJ, 8Merck & Co., Inc., Kenilworth, NJ, USA, Kenilworth, NJ

    Background/Purpose: LOFT was a double-blind, placebo-controlled trial. Women ≥65 years with total hip (TH) or femoral neck (FN) bone mineral density (BMD) T-score ≤-2.5, or…
  • Abstract Number: 352 • 2015 ACR/ARHP Annual Meeting

    Low Bone Density Is Associated with Atherosclerotic Disease in Patients with Psoriatic Arthritis

    Eirik Ikdahl1,2, Hege Kilander Høiberg3, Silvia Rollefstad2, Andreas P Diamantopoulos4,5, Grunde Wibetoe2, Arthur Kavanaugh6, Inge C Olsen7, Tore K. Kvien7, Anne Grete Semb8 and Glenn Haugeberg9, 1Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 2Preventive Cardio-Rheuma Clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 3Department of Rheumatology, Hospital of Southern Norway, Kristiansand, Norway, 4Rheumatology, Haugesund Hospital for Rheumatic Diseases, Haugesund, Norway, 5Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, 6University of California San Diego, La Jolla, CA, 7Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 8Diakonhjemmet Hospital, Oslo, Norway, 9Rheumatology, The Norwegian University of Science and Technology, Trondheim, Norway

    Background/Purpose: There is an evidence vacuum concerning the mechanisms underlying the high atherosclerotic cardiovascular disease (ASCVD) burden in patients with psoriatic arthritis (PsA). In the…
  • Abstract Number: 367 • 2015 ACR/ARHP Annual Meeting

    Prevention and Treatment of Bone Loss Following Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis

    Xerxes Pundole1, Maria A. Lopez-Olivo2, Hira Cheema3, Gabriela Sanchez Petitto4, Maria E. Suarez-Almazor5 and Huifang Lu6, 1General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, 2Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, 3Texas Tech Odessa, Odessa, TX, 4The University of Texas, Health Science Center, Houston, TX, 5The Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, 6General Internal Medicine, AT &EC, The University of Texas, MD Anderson Cancer Center, Houston, TX

    Background/Purpose: The main goal of our study was to evaluate the efficacy and safety of bisphosphonates and/or general preventive strategies in the prevention and treatment…
  • Abstract Number: 380 • 2015 ACR/ARHP Annual Meeting

    Osteoporosis Screening and Treatment of Rheumatoid Arthritis Patients at a Teaching Institution

    Sheena Ogando1, Calie Santana2, Irene Blanco3 and Barbara Mendez1, 1Rheumatology, Montefiore Medical Center, Bronx, NY, 2Medicine, Montefiore Medical Center, Bronx, NY, 3Rheumatology, Albert Einstein College of Medicine, Bronx, NY

    Background/Purpose:   Glucocorticoids are effective at treating rheumatologic diseases but are known to increase fracture risk.  In 2010, the ACR developed recommendations for the prevention…
  • Abstract Number: 830 • 2015 ACR/ARHP Annual Meeting

    Calcinosis Is Associated with Digital Ulcers and Osteoporosis in Patients with Systemic Sclerosis

    Antonia Valenzuela1, Murray Baron2, Ariane L. Herrick3, Susana Proudman4, Wendy Stevens5, Tatiana Sofia Rodriguez-Reyna6, Alessandra Vacca7, Thomas A. Medsger Jr.8, Monique Hinchcliff9, Vivien Hsu10, David Fiorentino11, Lorinda Chung12 and the Canadian Scleroderma Research Group, and the ASIG rubric, 1Stanford University School of Medicine, Stanford, CA, 2Rheumatology, McGill University, Jewish General Hospital, Montreal, QC, Canada, 3Centre for Musculoskeletal Research, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, 4Rheumatology Unit, Royal Adelaide Hospital North Terrace, Adelaide, Australia, 5Department of Rheumatology, St. Vincent’s Hospital Melbourne, Melbourne, Australia, 6Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 7University Hospital of Cagliari, Rheumatology Unit, Monserrato, Italy, 8Department of Medicine/Rheumatology, University of Pittsburgh, Pittsburgh, PA, 9Rheumatology, Northwestern University, Chicago, IL, 10Rheumatology, RWJ Med Schl Scleroderma Prog, New Brunswick, NJ, 11Department of Dermatology, Stanford University School of Medicine, Palo Alto, CA, 12Stanford University, Palo Alto, CA

    Background/Purpose: Calcinosis is a debilitating complication of systemic sclerosis (SSc). We sought to determine the clinical factors associated with calcinosis in an international multi-center collaborative…
  • Abstract Number: 2165 • 2015 ACR/ARHP Annual Meeting

    Awareness and Reasons for Lack of Post-Fracture Osteoporosis Therapy: A Survey of Post-Menopausal Women

    Denise Boudreau1, Onchee Yu1, Akhila Balasubramanian2, Jane Grafton1, Heidi Wirtz3, Andreas Grauer3, D. Barry Crittenden3 and Delia Scholes1, 1Group Health Research Institute, Seattle, WA, 2Center for Observational Research, Amgen, Inc., Thousand Oaks, CA, 3Amgen Inc., Thousand Oaks, CA

    Background/Purpose: Osteoporotic fractures cause patient morbidity and increase risk for future fracture. Effective drug therapies for osteoporosis (OP) are available, yet only a minority of…
  • Abstract Number: 2509 • 2015 ACR/ARHP Annual Meeting

    Glucocorticoid Induced Osteoporosis Screening and Treatment: A Gender Comparison in a Cohort of Patients with Underlying Rheumatologic Diagnosis in a Tertiary Care Setting

    Hajra Shah1, Narender Annapureddy2 and Ruchi Jain1, 1Rheumatology, Rush University Medical Center, Chicago, IL, 2Rheumatology and Immunology, Vanderbilt University, Nashville, TN

    Background/Purpose: One-fourth of hip fractures occur in men. Men treated with oral glucocorticoids for at least 3 months are particularly at risk. Studies have suggested…
  • Abstract Number: 919 • 2014 ACR/ARHP Annual Meeting

    Glucocorticoid Exposure and Fracture Risk in a Large Cohort of Commercially-Insured Rheumatoid Arthritis Patients Under Age 65

    Akhila Balasubramanian1, Sally Wade2, Robert A Adler3, Celia Fang (Lin)4, Michael Maricic5, Cynthia O'Malley1, Kenneth G. Saag6 and Jeffrey R. Curtis7, 1Center for Observational Research, Amgen, Inc., Thousand Oaks, CA, 2Wade Outcomes Research and Consulting, Salt Lake City, UT, 3Internal Medicine, Hunter Holmes McGuire VA Medical Center, Richmond, VA, 4Amgen, Thousand Oaks, CA, 5Catalina Pointe Rheumatology, Tucson, AZ, 6Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, 7The University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose Systemic glucocorticoid use can increase fracture risk, although dose-specific effects are not well understood, especially in younger adults.  Underlying diseases (e.g., rheumatoid arthritis [RA])…
  • Abstract Number: 916 • 2014 ACR/ARHP Annual Meeting

    Effects of 2 Years of Treatment with Romosozumab Followed By 1 Year of Denosumab or Placebo in Postmenopausal Women with Low Bone Mineral Density

    MR McClung1, A Chines2, JP Brown3, A Diez-Perez4, H Resch5, J Caminis6, MA Bolognese7, S Goemaere8, HG Bone9, JR Zanchetta10, J Maddox2, O Rosen2, S Bray11 and A Grauer2, 1Oregon Osteoporosis Center, Portland, OR, 2Amgen Inc., Thousand Oaks, CA, 3Laval University and CHU de Québec Research Centre, Quebec City, QC, Canada, 4Autonomous University of Spain, Barcelona, Spain, 5St. Vincent Hospital, Vienna, Austria, 6UCB, Raleigh, NC, 7Bethesda Health Research Center, Bethesda, MD, 8Ghent University Hospital, Ghent, Belgium, 9Michigan Bone and Mineral Clinic, Detroit, MI, 10Instituto de Investigaciones Metabólicas, Buenos Aires, Argentina, 11Amgen Ltd., Cambridge, United Kingdom

    Background/Purpose: We previously reported that 1 year of treatment with the sclerostin antibody romosozumab (Romo) was associated with increased bone mineral density (BMD) and bone…
  • Abstract Number: 232 • 2014 ACR/ARHP Annual Meeting

    Significance of Serum Srankl and Osteoprotegerin Concentration in Patients with Rheumatoid Arthritis

    Kotaro Shikano, Kaichi Kaneko, Mai Kawazoe, Shotaro Masuoka, Hiroshi Sato, Emiko Shindo, Natsuki Fujio, Makoto Kaburaki, Sei Muraoka, Nahoko Tanaka, Tatsuhiro Yamamoto, Kenji Takagi, Natsuko Kusunoki, Tomoko Hasunuma and Shinichi Kawai, Division of Rheumatology, Department of Internal Medicine, School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan

    Background/Purpose Rheumatoid arthritis (RA) is known as a cause of secondary osteoporosis. The previous studies reported that receptor activator for nuclear factor κB ligand (RANKL)…
  • Abstract Number: 111 • 2014 ACR/ARHP Annual Meeting

    Low Rates of Bone Mineral Density Testing in Medicare Beneficiaries with Breast Cancer Starting Aromatase Inhibitor Therapy

    Mamatha Siricilla1, Ruili Luo2, Linda Elting2 and Maria E. Suarez-Almazor1, 1The Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, 2The Department of Health Services Research, The University of Texas, MD Anderson Cancer Center, Houston, TX

    Background/Purpose Aromatase inhibitors (AI) are increasingly used as adjuvant hormonal therapy in postmenopausal women with estrogen receptor-positive breast cancer. It is well recognized that therapy…
  • Abstract Number: 50 • 2014 ACR/ARHP Annual Meeting

    Incidence and Risk Factors for Osteoporotic Vertebral Fracture in Low-Income Community-Dwelling Elderly: A Population-Based Prospective Cohort Study in Brazil. the São Paulo Ageing & Health (SPAH) Study

    Diogo S. Domiciano1, Luana G. Machado2, Jaqueline B. Lopes2, Valéria Caparbo2, Liliam Takayama2, Ricardo M. Oliveira3 and Rosa M. R. Pereira4, 1Rheumatology, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil, 2Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 3RDO Diagnosticos Medicos, São Paulo, Brazil, 4Reumatologia, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil

    Background/Purpose: Vertebral fractures are associated with increased future fracture risk and mortality. No data on incidence of osteoporotic vertebral fracture have been reported in low-income…
  • Abstract Number: 2314 • 2014 ACR/ARHP Annual Meeting

    Dexa Testing in Long-Term Steroid Use

    Beth Scholz, Internal medicine, University of Texas Health Science Center at Houston, Houston, TX

    Background/Purpose: Risk stratification in the ACR glucocorticoid-induced osteoporosis guidelines includes DEXA testing, which is not universally implemented at our rheumatology clinic. DEXA utilization should be…
  • Abstract Number: 2315 • 2014 ACR/ARHP Annual Meeting

    Glucocorticoid Induced Osteoporosis Screening and Treatment in a Cohort of Male Patients with Underlying Rheumatologic Diagnosis in a Tertiary Care Setting

    Hajra Shah, Narender Annapureddy, Joel A. Block and Ruchi Jain, Rheumatology, Rush University Medical Center, Chicago, IL

    Background/Purpose: One-fourth of hip fractures occur in men. Three groups of men are at high risk for fracture: those who have already suffered a fragility…
  • « Previous Page
  • 1
  • …
  • 16
  • 17
  • 18
  • 19
  • 20
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology